This platform is currently totally free and created by doctors. 🩺
Menu
SpecialtiesDrug IndexGuidelinesClassificationsPricing
Login
HomeDrug IndexClinical Monograph

Arformoterol Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Navigation

DRUG NAME: Arformoterol
Therapeutic Class: Bronchodilator
Subclass: Long-acting β2-adrenergic agonist (LABA)
Speciality: Pulmonology
Schedule (India): Schedule H
Route(s): Inhalation (nebulised)
Formulations Available in India:
  • Inhalation solution for nebulisation: 15 mcg/2 mL unit-dose vial (respule)

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

▶ Chronic Obstructive Pulmonary Disease (COPD) — Maintenance Treatment
Parameter Recommendation
Starting dose
 15 mcg via nebulisation twice daily (morning and evening)
Titration
 Not applicable — fixed-dose regimen; use lowest effective dose
Usual maintenance dose
 15 mcg twice daily
Maximum dose
 30 mcg/day (administered as 15 mcg twice daily)
Clinical Notes:
  • NOT for acute bronchospasm or rescue therapy
  • Doses should be approximately 12 hours apart
  • Do not exceed recommended daily dose — risk of β2-agonist toxicity
  • Each unit-dose vial is for single use only; discard unused portion
  • Administer via standard jet nebuliser connected to air compressor
Important — Asthma Use:
  • NOT approved for asthma monotherapy
  • LABA monotherapy in asthma is associated with increased risk of asthma-related deaths
  • If considered for asthma, must always be used with concomitant inhaled corticosteroid (ICS)
  • Specialist pulmonologist supervision required
  • DPI combinations (ICS + LABA) preferred in asthma management

Secondary Indications — Adults Only (Off-label)

Not applicable. No established off-label indications in Indian practice.

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

▶ COPD in Adolescents ≥12 Years — SPECIALIST ONLY
Parameter Recommendation
Starting dose
 15 mcg via nebulisation twice daily
Titration
 Not applicable
Usual maintenance dose
 15 mcg twice daily
Maximum dose
 30 mcg/day
Clinical Notes:
  • COPD is rare in adolescents; use only with confirmed diagnosis under pulmonologist care
  • Not recommended below 12 years of age due to lack of safety and efficacy data

Secondary Indications — Paediatrics (Off-label)

Indication Details
Asthma (as adjunct to ICS) — OFF-LABEL
 NOT RECOMMENDED in children; no strong Indian data for nebulised arformoterol in paediatric asthma. DPI-based ICS + LABA combinations preferred. Specialist pulmonologist decision only. Avoid unless no alternatives available.
Safety Monitoring (Paediatric):
  • Monitor for tremor, tachycardia, palpitations
  • Watch for paradoxical bronchospasm
  • Assess growth if on concurrent high-dose ICS
  • Periodic pulse and blood pressure monitoring
Age Restrictions:
  • NOT RECOMMENDED below 12 years of age except under specialist supervision with no alternative options

RENAL ADJUSTMENT

Renal Function Recommendation
All stages of renal impairment No dose adjustment required
Haemodialysis / Peritoneal dialysis No specific data; systemic exposure is minimal with inhalation route

HEPATIC ADJUSTMENT

Severity Recommendation
Mild impairment
 No dose adjustment required
Moderate impairment
 No dose adjustment required; monitor for adverse effects
Severe impairment
 Use with caution — limited data available; monitor closely for systemic effects

CONTRAINDICATIONS

  • Known hypersensitivity to arformoterol, formoterol, or any component of the formulation
  • Primary treatment of acute bronchospasm or status asthmaticus (not a rescue medication)
  • Monotherapy in asthma without concurrent inhaled corticosteroid
  • Life-threatening deterioration of asthma

CAUTIONS

  • Cardiovascular disease (coronary artery disease, arrhythmias, hypertension) — risk of cardiovascular adverse effects
  • Hyperthyroidism — may exacerbate symptoms
  • Seizure disorders — β2-agonists may lower seizure threshold
  • Hypokalaemia — can further reduce serum potassium; risk increased with concurrent diuretics, steroids, or hypoxia
  • Diabetes mellitus — may cause transient hyperglycaemia
  • Pheochromocytoma (rare)
  • QT prolongation risk — caution in patients with baseline QT prolongation or on QT-prolonging drugs
  • Switching from another LABA — ensure appropriate washout; do not combine multiple LABAs
  • Paradoxical bronchospasm — discontinue immediately if occurs

PREGNANCY

Aspect Details
Overall safety
 Limited human data; use only if potential benefit justifies potential risk to fetus
When to use
 Moderate-severe COPD uncontrolled with short-acting bronchodilators alone; specialist input recommended
Preferred alternatives
 Salmeterol or budesonide/formoterol combinations (more pregnancy experience available)
Monitoring required
 Maternal heart rate; uterine activity if used near term (β2-agonists may inhibit uterine contractions)

LACTATION

Aspect Details
Compatibility
 Likely compatible — minimal systemic absorption with inhalation route
Expected levels in milk
 Low (systemic exposure is minimal)
Preferred alternatives
 Salmeterol (more lactation data available)
Infant monitoring
 Irritability, jitteriness, feeding difficulties, tachycardia

ELDERLY

Aspect Recommendation
Starting dose
 15 mcg twice daily (same as general adult population)
Titration
 Not applicable; use lowest effective dose
Extra risks
 Greater susceptibility to cardiovascular adverse effects (tachycardia, arrhythmias, hypertension); consider baseline ECG if cardiac history; monitor for hypokalaemia especially if on diuretics
Monitoring
 Periodic ECG monitoring recommended in patients with cardiac comorbidities

MAJOR DRUG INTERACTIONS

Interacting Drug Effect/Risk Management
Non-selective β-blockers (propranolol, carvedilol)
 Antagonise bronchodilator effect; may precipitate severe bronchospasm in COPD/asthma Avoid combination; if β-blocker essential, use cardioselective agent (bisoprolol, metoprolol) with caution
MAO inhibitors
 Potentiate cardiovascular effects of β2-agonists; risk of hypertensive crisis Avoid within 14 days of MAO inhibitor use
Tricyclic antidepressants (amitriptyline, imipramine)
 Potentiate cardiovascular effects; may prolong QT interval Avoid combination or use with extreme caution; monitor ECG
Other LABAs (salmeterol, formoterol, indacaterol)
 Additive β2-agonist toxicity; no additional benefit Do not use concurrently; only one LABA at a time
Sympathomimetic agents (oral decongestants, adrenaline)
 Additive cardiovascular effects Avoid concurrent use or use with caution

MODERATE DRUG INTERACTIONS

Interacting Drug Effect/Risk Management
Non-potassium-sparing diuretics (furosemide, hydrochlorothiazide)
 Additive hypokalaemia risk Monitor serum potassium; supplement if needed
Corticosteroids (systemic)
 May potentiate hypokalaemia with prolonged use Monitor potassium levels with prolonged co-administration
Theophylline/aminophylline
 Additive sympathomimetic effects (tachycardia, tremor, CNS stimulation) Monitor heart rate and CNS symptoms; adjust doses if needed
Macrolide antibiotics (erythromycin, azithromycin, clarithromycin)
 Potential QT prolongation Monitor ECG in susceptible patients
Fluoroquinolones (levofloxacin, moxifloxacin)
 Potential QT prolongation Monitor ECG; avoid moxifloxacin if possible
Xanthine derivatives
 Additive effects on heart rate and CNS Monitor for adverse effects

COMMON ADVERSE EFFECTS

  • Tremor (fine tremor of hands)
  • Palpitations
  • Tachycardia
  • Headache
  • Muscle cramps
  • Nausea
  • Throat irritation or dryness
  • Dizziness
  • Nervousness

SERIOUS ADVERSE EFFECTS

Adverse Effect Notes
Paradoxical bronchospasm Requires immediate discontinuation; treat with short-acting bronchodilator
Severe hypokalaemia Risk of cardiac arrhythmias; monitor electrolytes especially with concurrent diuretics
QT prolongation / Torsades de Pointes Rare; monitor ECG in high-risk patients
Angina / Myocardial ischaemia Discontinue if suspected; avoid in unstable cardiac disease
Severe hypertension Monitor BP; reduce dose or discontinue if severe
Seizures Rare; use with caution in epilepsy
Anaphylaxis / Severe hypersensitivity Discontinue immediately; provide emergency treatment

MONITORING REQUIREMENTS

Timing Parameters
Baseline
 Spirometry (FEV1, FVC); ECG if cardiac history or risk factors; serum potassium if on diuretics or at risk of hypokalaemia; heart rate and blood pressure
After initiation (1–2 weeks)
 Symptom control assessment; monitor for tremor, palpitations, tachycardia; check potassium if indicated
Long-term
 Annual spirometry; periodic ECG in patients with cardiac comorbidities or on QT-prolonging drugs; serum electrolytes in at-risk populations; reassess need for continued LABA therapy

BRANDS AVAILABLE IN INDIA

  • Brovana Respules
  • Arforte Respules
  • Larbigen (15 mcg respules)
  • Arform (Cipla)
  • Aformes (Sun Pharma)

PRICE RANGE (INR)

Formulation Price Range Notes
15 mcg/2 mL unit-dose respule ₹20–₹35 per respule Price varies by brand
Pack of 10 respules ₹180–₹300 per pack Commonly dispensed pack size
  • Not under NLEM price control
  • Available in private retail pharmacies
  • Government supply availability varies by state

CLINICAL PEARLS

  1. NOT a rescue medication — arformoterol has slow onset; always ensure patient has access to a short-acting bronchodilator (salbutamol nebulisation or MDI) for acute symptoms.
  2. Never use LABA monotherapy in asthma — associated with increased asthma-related deaths; must always combine with ICS if used in asthma.
  3. Nebuliser technique matters — ensure patients use a standard jet nebuliser with adequate flow rate (6–8 L/min); ultrasonic nebulisers not recommended.
  4. Watch for hypokalaemia — especially relevant in patients on diuretics, systemic steroids, or during acute exacerbations with hypoxia; monitor potassium in at-risk patients.
  5. One LABA only — do not combine with other long-acting β2-agonists (salmeterol, formoterol, indacaterol); no additional efficacy and increased toxicity risk.
  6. Consider step-down — if patient achieves good symptom control for ≥3 months, reassess need for continued LABA or possibility of switching to ICS-LABA DPI combination if appropriate.

TAGS

arformoterol; COPD; LABA; bronchodilator; nebuliser; respiratory; maintenance therapy; Schedule H; NLEM-excluded; pulmonology

VERSION

RxIndia v0.9 — 28 February 2026

REFERENCES

  • CDSCO approved product information
  • Indian Pharmacopoeia
  • AIIMS Adult COPD Management Protocol
  • API Textbook of Medicine
  • Goodman & Gilman’s The Pharmacological Basis of Therapeutics (pharmacology reference)
  • GOLD Guidelines (supportive reference for COPD management)
⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

All feedback is reviewed by our clinical editorial team.